ANDOVER, Mass. , Sept. 27, 2024 /PRNewswire/ -- TransMedics Group, Inc.
("TransMedics") (Nasdaq: TMDX ), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on September 24, 2024 , TransMedics granted non-qualified stock options to purchase an aggregate of 336 shares of its common stock and an aggregate of 218 restricted stock units to 1 employee, each as a material inducement for the employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.
TransMedics granted non-qualified stock options to purchase 336 shares of TransMedics' common stock and 218 restricted stock units in the aggregate. The stock options were granted with a per share exercise price of $156.00 , the closing price of the common stock on the Nasdaq Global Market on September 24, 2024 .
Twenty-five percent of the shares subject to each option will vest on the first yearly anniversary of the date of the employee's start of employment, with the remainder vesting in equal monthly installments over the subsequent three year period, subject to the employee's continued service with the Company through the applicable vesting date. The options have a 10-year term and are subject to the terms of the TransMedi.
